BridgeBio Pharma, Inc. - Common Stock — Cash Flow (NASDAQ:BBIO) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Cash from operating activities -399.71 M-497.93 M-419.49 M-527.72 M-520.73 M-445.91 M -434.37 M Cash from investing activities -52.99 M-200.83 M453.15 M54.03 M60.78 M-24.49 M -34.74 M Cash from financing activities 447.19 M736.45 M-13.13 M451.54 M748.46 M359.29 M 398.05 M Free cash flow -399.71 M-497.93 M-419.49 M-527.72 M-520.73 M-455.5 M -437.79 M

News

BridgeBio Q2 Sales Jump 120% as Attruby Drives Commercial Momentum

Is BBIO a Buy as Fast Sales Growth Meets a Steep Valuation Premium?

Why BBIO Rose 24% in Three Months and Whether the Rally Can Continue

BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months (NASDAQ:BBIO)

BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge

4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year

BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript

BridgeBio Pharma (BBIO) Reports Q2 Loss, Tops Revenue Estimates

The Week That Was, The Week Ahead: Macro and Markets, August 9 - TipRanks.com

Viatris Gears Up to Report Q2 Earnings: What's in the Cards?

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?

Tracking Ole Andreas Halvorsen’s Viking Global Portfolio – Q1 2026 Update